Abstract:Background: Prolactinomas usually exhibit a benign course and can be safely and effectively managed by dopamine agonists (DA). However, some are locally invasive and may show resistance to DA therapy, and the management of such cases remains controversial. The aim of the present study was to determine whether histological features and markers of cell proliferation correlated to the clinical behaviour of prolactinomas and with DA resistance. Method: This retrospective study included 74 cases (36 men and 38 women) who had monohormonal prolactinomas removed by transsphenoidal surgery. The prolactinomas were categorized on the basis of tumour size (48 macroadenomas), invasion of the cavernous sinus (n = 31), and resistance to bromocriptine (BRC) therapy (n = 14). Group 1 consisted of non-invasive microprolactinomas (n = 24), group 2 of non-invasive macroprolactinomas (n = 19), group 3 of invasive non-BRC-resistant tumours (n = 19), and group 4 of invasive BRC-resistant tumours (n = 12). The later group included one case of carcinoma with bone and lung metastases. Seven additional parameters were studied, these being age, sex, basal prolactin (PRL) levels, the Ki-67 and PCNA labelling indices (LI), mitotic count, and cellular atypia. Findings: Age and preoperative PRL levels did not correlate to the histological parameters studied. Tumour size and invasion were related to cellular atypia and the Ki-67 LI. BRC-resistant tumours were more frequently invasive (12/14) than BRC-responsive tumours (11/30; p = 0.002) and were more frequent in men than in women (33 versus 5%; p = 0.003). BRC-resistant tumours had a higher Ki-67 LI and mitotic count (4.2+/-2.0% and 4+/-1, respectively) than other tumours (0.7+/-0.2% and 1+/-0, respectively; p<0.05). The strongest correlations with tumoural staging were seen with male sex and high mitotic activity. Six out of the 12 invasive BRC-resistant macroprolactinomas, including the PRL secreting carcinoma, exhibited histological features of aggressiveness (a mitotic count >/=3 [i.e. in the fourth quartile] and/or a high Ki-67 LI and cellular atypia). Conclusions: In this surgical retrospective series, histological signs of aggressiveness are present in 50% of invasive and BRC-resistant prolactinomas, which are more frequent in men than in women. This fits with the behaviour of BRC-resistant prolactinomas, which can continue to grow despite DA treatment. These findings justify the long-term follow up of these tumours, and the use of surgery and/or radiotherapy if there is concern about the control of tumour growth.

Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas.

Bromocriptine and Cabergoline Induce Cell Death in Prolactinoma Cells Via the ERK/EGR1 and AKT/mTOR Pathway Respectively

Inhibition of Skp2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells

Combined Treatment with Artesunate and Bromocriptine Has Synergistic Anticancer Effects in Pituitary Adenoma Cell Lines.

Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline.

Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death

Curative Effect and Mechanism of Bromocriptine on Pituitary Prolactinoma

Long-term treatment with bromocriptine inhibits endometrial adenocarcinoma development in rats

Activation of DRD5 (dopamine Receptor D5) Inhibits Tumor Growth by Autophagic Cell Death

Bafilomycin A1 Induces Caspase-Dependent Apoptosis and Inhibits Autophagy Flux in Diffuse Large B Cell Lymphoma

Bromocriptine Treatment of Invasive Giant Prolactinomas Involving the Cavernous Sinus: Results of a Long-Term Follow Up.

Down-Regulation of Bcl-2 Enhances Autophagy Activation and Cell Death Induced by Mitochondrial Dysfunction in Rat Striatum

Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline Against Pituitary Adenomas

Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years

Targeted Inhibition of Mtor by BML-275 Induces Mitochondrial-Mediated Apoptosis and Autophagy in Prostate Cancer.

Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance

Cabergoline Versus Bromocriptine for the Treatment of Giant Prolactinomas: A Quantitative and Systematic Review

Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine

Cabergoline for the Treatment of Bromocriptine-Resistant Invasive Giant Prolactinomas

Pseudolaric Acid B Induced Autophagy, but Not Apoptosis, in MRC5 Human Fibroblast Cells.

Metformin promotes apoptosis of rat prolactinoma MMQ cells by inducing autophagy